Journal of Stem Cell Research & Therapy

Using Mouse Clone Model to open the door for human iPSC therapy

7^th Annual Conference on Stem Cell and Regenerative Medicine

August 04-05, 2016 Manchester, UK

Gang Zhang

Interventional Hospital of Shandong Red Cross Society and Cell Biotechnology Co. Ltd., China

Keynote: J Stem Cell Res Ther

Abstract:

IPSC is one of the most astonishing accomplishments at the 21st century. It not only laid the foundation for the research of reprogramming, but also provided priceless sources for stem cell therapy. However, could iPSCs eventually be adapted into clinical therapy? It is well known that pluripotent stem cells, including ESCs and iPSCs can form tumors and also result in immune rejection. So far, it is uncertain whether tumor-formation and immune-rejection resulted from immune-deficient recipient mice or the donor stem cells. To overcome this confusion, we designed a new mouse model, called �??Mouse Clone Model�?�. This method grants us the ability to generate a grand population of cloned mice and each of them would be originated from the same ICM. When we use them as donors for iPSCs, they would be the same with the original donor ESCs. As a result, we can theoretically perform stem cell transplantation between iPSCs and these mice could mimic the transplantation of iPSCs from the patients into themselves. Our �??Mouse Clone Model�?� has several advantages. Firstly, we can test immunorejection of iPSCs and various tissue specific stem cells. Secondly, we can assess the tumor formation of iPSCs and other stem cell lines. Finally but not lastly, we can investigate the appropriate stages of different stem cells for transplantation. We suggest the stem cell researchers all over the world to investigate the applicability of iPSCs and tissue specific stem cells for therapeutic applications and take advantage of this model.

Biography :

Gang Zhang has completed his PhD in 2005 from Institute of Zoology, Chinese Academy of Sciences and obtained his Postdoctoral studies from University of Toronto and Harvard Medical School from 2005 to 2015. He discovered the “All or Half” law of recombinant DNA and designed “Mouse Clone Model” to assess the immune-rejection and tumor-formation of iPSCs. Currently, he is the General Director for Research and Development of Interventional Hospital of Shandong Red Cross Society, one of the top hospitals in China. He has published more than 20 papers in reputed journals and is the Editor of 9 famous international journals.

Email: gang.zhang@utoronto.ca